Literature DB >> 18174175

Up-regulation of nicotinic receptors by nicotine varies with receptor subtype.

Heather Walsh1, Anitha P Govind, Ryan Mastro, J C Hoda, Daniel Bertrand, Yolanda Vallejo, William N Green.   

Abstract

Recent evidence suggests that in addition to alpha4beta2 and alpha3-containing nicotinic receptors, alpha6-containing receptors are present in midbrain dopaminergic neurons and involved in the nicotine reward pathway. Using heterologous expression, we found that alpha6beta2, like alpha3beta2 and alpha4beta2 receptors, formed high affinity epibatidine binding complexes that are pentameric, trafficked to the cell surface, and produced acetylcholine-evoked currents. Chronic nicotine exposure up-regulated alpha6beta2 receptors with differences in up-regulation time course and concentration dependence compared with alpha4beta2 receptors, the predominant high affinity nicotine binding site in brain. The alpha6beta2 receptor up-regulation required higher nicotine concentrations than for alpha4beta2 but lower than for alpha3beta2 receptors. The alpha6beta2 up-regulation occurred 10-fold faster than for alpha4beta2 and slightly faster than for alpha3beta2. Our data suggest that nicotinic receptor up-regulation is subtype-specific such that alpha6-containing receptors up-regulate in response to transient, high nicotine exposures, whereas sustained, low nicotine exposures up-regulate alpha4beta2 receptors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18174175     DOI: 10.1074/jbc.M703432200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

2.  GABA acts as a ligand chaperone in the early secretory pathway to promote cell surface expression of GABAA receptors.

Authors:  Randa S Eshaq; Letha D Stahl; Randolph Stone; Sheryl S Smith; Lucy C Robinson; Nancy J Leidenheimer
Journal:  Brain Res       Date:  2010-05-16       Impact factor: 3.252

3.  The nicotine metabolite, cotinine, alters the assembly and trafficking of a subset of nicotinic acetylcholine receptors.

Authors:  Ashley M Fox; Faruk H Moonschi; Christopher I Richards
Journal:  J Biol Chem       Date:  2015-08-12       Impact factor: 5.157

Review 4.  Inside-out neuropharmacology of nicotinic drugs.

Authors:  Brandon J Henderson; Henry A Lester
Journal:  Neuropharmacology       Date:  2015-02-04       Impact factor: 5.250

5.  Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists.

Authors:  Roger L Papke; Caryn Trocmé-Thibierge; Daniela Guendisch; Shehd Abdullah Abbas Al Rubaiy; Stephen A Bloom
Journal:  J Pharmacol Exp Ther       Date:  2011-02-01       Impact factor: 4.030

6.  Nicotinic receptors regulate the dynamic range of dopamine release in vivo.

Authors:  Jessica L Koranda; Jackson J Cone; Daniel S McGehee; Mitchell F Roitman; Jeff A Beeler; Xiaoxi Zhuang
Journal:  J Neurophysiol       Date:  2013-10-02       Impact factor: 2.714

Review 7.  Cellular events in nicotine addiction.

Authors:  Rachel E Penton; Robin A J Lester
Journal:  Semin Cell Dev Biol       Date:  2009-01-20       Impact factor: 7.727

Review 8.  Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders.

Authors:  Maryka Quik; Xiomara A Perez; Sharon R Grady
Journal:  Biochem Pharmacol       Date:  2011-06-13       Impact factor: 5.858

9.  Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling.

Authors:  Vinay Parikh; Jinzhao Ji; Michael W Decker; Martin Sarter
Journal:  J Neurosci       Date:  2010-03-03       Impact factor: 6.167

10.  Choline promotes nicotinic receptor alpha4 + beta2 up-regulation.

Authors:  Lorise C Gahring; Gustavo A Vasquez-Opazo; Scott W Rogers
Journal:  J Biol Chem       Date:  2010-04-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.